Shots: The US FDA’s CRDAC voted 12 to 1 supporting the use of Entresto (sacubitril/valsartan) in the treatment of patients with HFpEF The decision was based on efficacy & safety analyses, including findings from a pre-specified subgroup analysis of PARAGON-HF (P-III study in HFpEF) and additional evidence from PARAMOUNT (P-II trial in HFpEF), as well […]Read More
Shots: The P-III PARAGON-HF study involves assessing of Entresto vs valsartan in 4,822 HF patients with preserved ejection fraction, resulted in 13% reduction in HF hospitalization and CV death, 15% reduction in total HF hospitalization but narrowly missed the statistical significance, patients with left ventricular ejection fraction ≤57% median showed greater effect The P-IV PROVE-HF […]Read More
Shots: Henry to get an exclusive option to license US patent application 14/654,140 for Galectin-3 inhibitors and will acquire minority equity in G3 Pharmaceuticals The focus of the agreement is to advance therapies for heart failure with preserved ejection fraction (HFpEF) without no approved treatments Galectin-3 is a protein for oral use and is indicated […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
